Of the the 3 indications that want a CR, have had 1, in the one, with least commercial scaleabilty . Reasons already discussed with method of administration and shortage of not only expertise but those within neuro field currently trained.
The two trials currently running with one, only one of type and other with real commercial opportunity, offer best opportunity for re-rate. Albeit the NK trial may be released later in year.
In the meantime, RMcQ can continue to look at changes to method of administration to tackle Glioblastoma because there will not be an increase in neurologists nor those skilled to administer at site.
If the above can be overcome, it would bring me, great pleasure.
Feel genuine happiness for anyone involved in CR in CHM and IMU and their families.
MJ
Of the the 3 indications that want a CR, have had 1, in the one,...
Add to My Watchlist
What is My Watchlist?
